Premium
Cannabidiol for Dravet and Lennox‐Gastaut syndromes: NICE guidance
Author(s) -
Gaber Tarek
Publication year - 2020
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.661
Subject(s) - cannabidiol , dravet syndrome , nice , lennox–gastaut syndrome , epilepsy , cannabis , medicine , psychiatry , psychology , computer science , programming language
Recent NICE guidance on the use of cannabidiol for two rare epilepsy syndromes could be seen as a crucial step in the acceptance of a medical role for cannabis derivatives. Formal trial evidence and official recommendation for the use of what has been regarded by many as a controversial substance for medicinal use should help those who may derive benefit to access it.